BioMarin Enrolls First Participant in Phase 3 Trial of Vosoritide for Treatment of Children with Achondroplasia
12. Dezember 2016 08:29 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., Dec. 12, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that the company has initiated a global Phase 3 study for vosoritide, an analog of...
BioMarin to Attend Three Upcoming Investor Conferences
03. November 2016 08:30 ET
|
BioMarin Pharmaceutical Inc.
- Credit Suisse 25th Annual Healthcare Conference on November 7 in Scottsdale, Arizona - Jefferies 2016 London Healthcare Conference on November 16 in London - Citi 2016 Global Healthcare Conference...
BioMarin Announces Third Quarter 2016 Financial Results
27. Oktober 2016 16:03 ET
|
BioMarin Pharmaceutical Inc.
- Third Quarter 2016 Total BioMarin Revenues Increase 34% Year over Year to $280 million - Vimizim Net Product Revenues Increase 25% Year over Year to $81 million in the Third Quarter 2016 - Kuvan...
BioMarin Presents Vosoritide Data in Achondroplasia at American Society of Human Genetics (ASHG) 2016 Meeting
19. Oktober 2016 17:01 ET
|
BioMarin Pharmaceutical Inc.
Highest Dose (30 µg/kg/day) Shows Approximately 50% Increase in Mean Annualized Growth Velocity, Comparable with 15 µg/kg/day dose Consistent Safety Profile at High Dose Findings Support 15...
UK Regulatory Agency Approves Continued Enrollment in BioMarin Phase 1/2 Study of BMN 270 in Hemophilia A
13. Oktober 2016 16:01 ET
|
BioMarin Pharmaceutical Inc.
Phase 1/2 Study Expected to Resume by End of 2016 Requirement for Prophylactic Corticosteroids Removed SAN RAFAEL, Calif., Oct. 13, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc....
BioMarin to Host Third Quarter 2016 Financial Results Conference Call and Webcast on Thursday, October 27 at 4:30pm ET
11. Oktober 2016 08:30 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., Oct. 11, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will...
BioMarin Reviews Status of Exon 51 Composition of Matter and Method of Use Patent Interference Cases against Sarepta Therapeutics
21. September 2016 08:53 ET
|
BioMarin Pharmaceutical Inc.
BioMarin to Seek Review of Ruling in Composition of Matter Patent Interference (No. 106,008) Patent Trial and Appeal Board Ruled in BioMarin’s Favor on Method of Use (MOU) Patent Interference (No....
BioMarin Announces EMA Validation of Brineura™ (Cerliponase Alfa) Marketing Authorization Application for Treatment of CLN2 Disease, a Form of Batten Disease
15. September 2016 08:37 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., Sept. 15, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) announced today that the European Medicines Agency (EMA) validated the Marketing Authorization...
BioMarin Announces Two Oral and 16 Poster Presentations at Society for the Study of Inborn Errors of Metabolism 2016 Annual Meeting
08. September 2016 04:30 ET
|
BioMarin Pharmaceutical Inc.
SAN RAFAEL, Calif., Sept. 08, 2016 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced today that two oral and 16 poster presentations related to the company’s products and...
BioMarin Announces Update to Brineura™ (Cerliponase Alfa) Program for Treatment of CLN2 Disease, a Form of Batten Disease
06. September 2016 16:05 ET
|
BioMarin Pharmaceutical Inc.
Additional Data Submitted to BLA following FDA Request, PDUFA Action Date Extended to April 27, 2017 Additional 8 Months of Treatment (81-Week Data) Show Maintenance of Efficacy, Consistent with...